Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.
Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.
An orphan disease with large unmet medical need.
Modus’ CEO, Christina Herder, to present the company at the 5th Annual Sickle Cell Disease Therapeutics Conference in New York.
Modus’ CEO, Christina Herder, presented the company at the 5th Annual Sickle Cell Disease Therapeutics.
In her presentation, Dr Herder will outline Modus Therapeutics’s development plans for sevuparin, a novel drug that it believes could offer a significant improvement of treatments in SCD.
Modus Therapeutics’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’.
I was curious to interview Christina Herder, the CEO of Modus Therapeutics, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates.
Modus Therapeutics AB announced Feb. 16, the Middle East University has shouldered some of the risk of developing sevuparin.
Sankt Eriksgatan 117,
SE-113 43 Stockholm, Sweden
+46 70 374 71 56
© 2016 Modus Therapeutics | All Rights Reserved